• 瀏覽: 212
  • 回覆: 3
巴西新聞網站今天引述2名檢視過疫苗效力評估的人士說法,稱由中國科興生物(Sinovac Biotech)研發的冠狀病毒疫苗在巴西境內晚期試驗的一般效力不到60%。



(中央社聖保羅11日綜合外電報導)巴西新聞網站今天引述2名檢視過疫苗效力評估的人士說法,稱由中國科興生物(Sinovac Biotech)研發的冠狀病毒疫苗在巴西境內晚期試驗的一般效力不到60%

與科興生物合作在巴西境內測試並生產這款疫苗的聖保羅布坦坦研究所(Instituto Butantan)駁斥這項報導「純屬推測」,研究所準備於當地時間明天中午12 時45分(台灣時間12日晚間11時45分)公布更完整的評估結果。

路透社報導,醫療專家和監管人員上週批評研究結果並沒有完整揭露。

布坦坦研究所所長柯瓦斯(Dimas Covas)指出,進行中的分析除了得出上週宣布的疫苗「臨床效力」外,也得到新的疫苗「一般效力」比率。布坦坦研究所正在巴西境內針對這款疫苗執行第3階段試驗。

巴西研究人員7日表示,這款疫苗顯示對2019冠狀病毒疾病(COVID-19)輕症具有78%效力,還能完全避免演變為重症,不過獨立專家呼籲對於這款名為CoronaVac、由中國科興生物研發的疫苗第3階段試驗公布更透明的研究結果。

印尼今天基於顯示這款疫苗具有65%效力的臨時資料,給予緊急使用批准。

巴西新聞網站UOL報導,布坦坦研究所明天將公布的疫苗效力會落在50%到60%之間,比衛生監管人員樹立的門檻要高,但遠低於上週看好的數字

訂閱《國際新聞》電子報 第一手掌握世界最新脈動

訂閱[/url]這款中國生產的疫苗,與牛津大學(Oxford University)及英國與瑞典合資阿斯特捷利康公司(AstraZeneca Plc)研發的疫苗在巴西都已申請緊急使用授權,正在等候監管機關放行。這場疫情在巴西奪走逾20萬人生命,病歿人數僅次美國。

全球針對CoronaVac疫苗的零碎研究結果引發憂慮,令人擔心中國生產商研發的疫苗不像美國和歐洲藥廠受到同樣的公眾監督

(譯者:李佩珊/核稿:張曉雯)
==============================================================================

吓!又話有效率78%,乜原來只係60%?  喂,咁樣唔得喎,公佈數據過程好似便秘咁,耐唔耐"必"少少出嚟,咁攪法我唔再考慮打科興㗎喇!

新聞來源連結:
https://www.cna.com.tw/news/aopl/202101120032.aspx

[ 本帖最後由 hfceddie 於 2021-1-12 10:48 AM 編輯 ]



台灣 "tw" 網站驚俾人話,貼埋路透社報導:

Sinovac's vaccine general efficacy less than 60% in Brazil trial - report


RASILIA (Reuters) - The CoronaVac COVID-19 vaccine developed by China's Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results.

Sao Paulo's Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report  "purely speculative.”

https://www.reuters.com/article/health-coronavirus-brazil-sinovac/sinovacs-vaccine-general-efficacy-less-than-60-in-brazil-trial-report-idUSS0N2II02Z

[ 本帖最後由 hfceddie 於 2021-1-12 10:49 AM 編輯 ]



Sinovac's vaccine general efficacy less than 60% in Brazil trial — report

AO PAULO — The coronavirus vaccine developed by China's Sinovac Biotech showed a general efficacy of less than 60% in its late-stage trial in Brazil, a news website reported on Monday, citing two people who seen the results.

Sao Paulo's Butantan biomedical center, which partnered with Sinovac to test and produce the vaccine in Brazil, dismissed the report as “purely speculative” as it prepares to release a more complete set of results on Tuesday at 12:45 p.m. (1545 GMT).

Medical experts and regulators criticized what they called an incomplete disclosure of study results last week.

Dimas Covas, director of the Butantan biomedical center, which is running a late-stage trial of the vaccine in Brazil, said ongoing analysis had yielded a new “general efficacy” rate in addition to the “clinical efficacy” announced last week.

On Thursday, Brazilian researchers said the vaccine was shown to be 78% effective against mild cases of COVID-19 and entirely prevented severe cases. But independent specialists called for more transparency on the findings from the Phase III trial of the Sinovac vaccine, known as CoronaVac.

The Philippines has secured 25 million doses of Sinovac vaccine, with the first 50,000 expected to arrive in February.

Brazilian news website UOL reported that the efficacy rate that Butantan was set to announce on Tuesday was between 50% and 60% — above the threshold set by health regulators, but well below the numbers celebrated last week.
   
Both the Chinese vaccine and a shot developed by Oxford University and British-Swedish firm AstraZeneca Plc have requests for emergency use authorization pending with regulators in Brazil, which has lost more than 200,000 lives to the pandemic – the worst death toll outside the United States.

Piecemeal disclosure of results from global CoronaVac studies have contributed to concerns that vaccines developed by Chinese producers are not subject to the same public scrutiny as U.S. and European alternatives.

In an interview with news website UOL on Monday, Covas said Butantan, which is funded by Sao Paulo state, had prioritized getting its data to Brazilian health regulator Anvisa and was still analyzing the results in parallel.

Covas said the institute would eventually provide its full data to a scientific conference to be announced this week.

Anvisa said on Saturday that a filing from Butantan seeking emergency use authorization for CoronaVac lacked some relevant information for analysis of the study, such as the age, gender and comorbidities of volunteers.

Covas said the federal agency's handling of the CoronaVac trial had raised questions about its independence, adding to tensions between Sao Paulo officials and the government of President Jair Bolsonaro, who had spurned the Chinese vaccine.

In Manila, Presidential spokesperson Harry Roque claimed that the Philippines is having a hard time procuring western brands of Covid-19 vaccine as rich nations have already secured the majority of future supplies.

Roque was responding to Senator Panfilo Lacson's question why concerned officials seemed to be “dribbling” or disregarding other vaccine brands and zeroing on buying CoronaVac, Sinovac’s COVID-19 vaccine.

“There's nothing spectacular about Sinovac other than it's proven safe and efficient—91.5% (efficacy rate) in at least 3 jurisdictions that we know of,” Roque said.

“At maski kung tanungin ang mga eksperto, ang mga vaccinologist eh inactivated po iyan ibig sabihin natural. Ito po ay pinahinang virus, which are the traditional vaccines that we have known for the past 300 years,” he added.
  
With report from Darryl John Esguerra, INQUIRER.net

https://newsinfo.inquirer.net/1382505/sinovacs-vaccine-general-efficacy-less-than-60-in-brazil-trial-report

[ 本帖最後由 hfceddie 於 2021-1-12 11:59 AM 編輯 ]



你打pfizer囉,最多歪嘴,唔會死


[按此隱藏 Google 建議的相符內容]